Cargando…

Recent Advances in Desmoid Tumor Therapy

The desmoid tumor is a locally aggressive proliferative disease within the family of soft-tissue sarcomas. Despite its relatively good prognosis, the clinical management of desmoid tumors requires constant multidisciplinary evaluation due to its highly variable clinical behavior. Recently, active su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napolitano, Andrea, Mazzocca, Alessandro, Spalato Ceruso, Mariella, Minelli, Alessandro, Baldo, Francesca, Badalamenti, Giuseppe, Silletta, Marianna, Santini, Daniele, Tonini, Giuseppe, Incorvaia, Lorena, Vincenzi, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463981/ https://www.ncbi.nlm.nih.gov/pubmed/32752153 http://dx.doi.org/10.3390/cancers12082135

Ejemplares similares

New frontiers in the medical management of gastrointestinal stromal tumours
por: Mazzocca, Alessandro, et al.
Publicado: (2019)

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Familial adenomatosis polyposis–related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
por: Napolitano, Andrea, et al.
Publicado: (2020)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)

Evidence-based guidelines: Improving AGREEment on consistence evaluation
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
por: Vincenzi, Bruno, et al.
Publicado: (2013)

Current and Emerging Biomarkers Predicting Bone Metastasis Development
por: Iuliani, Michele, et al.
Publicado: (2020)

Prognostic and predictive factors in pancreatic cancer
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Steroid-refractory immune related hepatitis may hide viral re-activation
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
por: Ruzzo, Annamaria, et al.
Publicado: (2014)

Brief letter of a doctor to his psychologist in the COVID-19 outbreak era
por: Santini, Daniele, et al.
Publicado: (2020)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas
por: Blanchi, Julie, et al.
Publicado: (2023)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Classic Kaposi Sarcoma: to treat or not to treat?
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_52hqhqgl50ipqdjp0ss15kg3k5